Get started
RocketTickers

Sorrento Receives FDA Clearance to Proceed With Phase 2 Study fo

Long
RocketTickers  
NASDAQ:SRNE   None
Beyond Technical Analysis
1
0
beyondta
SRNE: Sorrento Therapeutics, Inc.
2021-04-27 11:39:47
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.